Capital Fund Management S.A. Cassava Sciences Inc Transaction History

Capital Fund Management S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$9.57 - $35.08 $574,946 - $2.11 Million	60,078 Added 60.73%	159,000 $4.68 Million
Q2 2024 Aug 13, 2024	BUY	$12.35 - $26.11 $1.22 Million - $2.58 Million	98,922 New	98,922 $1.22 Million
Q4 2023 Feb 14, 2024	SELL	$12.64 - $30.11 $71,479 - $170,272	-5,655 Reduced 28.32%	14,310 $322,000
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $21,049 - $32,029	1,265 Added 6.76%	19,965 $332,000
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $403,733 - $521,356	18,700 New	18,700 $458,000

190

16.4M

3.49M

8.08M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $103M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.